AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER).
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
| Metabolism | Amino acids undergo transamination, deamination, and incorporation into proteins; dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation. |
| Excretion | Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination. |
| Half-life | Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation. |
| Protein binding | Minimal (<10%); amino acids and dextrose are not significantly bound to plasma proteins. |
| Volume of Distribution | Amino acids: ~0.3-0.5 L/kg (total body water). Dextrose: ~0.2 L/kg (extracellular fluid). Clinical meaning: rapid distribution into ECF and intracellular compartments. |
| Bioavailability | 100% IV; not administered via other routes. Oral/enteral bioavailability not applicable (TPN use only). |
| Onset of Action | IV infusion: Caloric effect within minutes; nitrogen balance improvement within 24-48 h. |
| Duration of Action | Continuous IV infusion: Effects persist during infusion; metabolic effects resolve within hours of discontinuation. Clinical note: TPN requires continuous administration to maintain anabolism. |
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: Reduce dose by 25-50%. GFR <30 mL/min: Avoid or reduce to 0.5-1 L/day with close monitoring of electrolytes and BUN. |
| Liver impairment | Child-Pugh A: Standard dosing. Child-Pugh B: Reduce to 50% of standard dose. Child-Pugh C: Avoid use due to risk of encephalopathy. |
| Pediatric use | Weight-based: 0.5-2 g/kg/day of amino acids (equivalent to 12-48 mL/kg/day of solution). Infusion rate not to exceed 0.1 g/kg/hour of amino acids. |
| Geriatric use | Start at lower end of dosing range (0.5-1 L/day) due to decreased renal function and metabolic reserve. Monitor for fluid overload and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER).
| Breastfeeding | This product is intended for parenteral nutrition; systemic levels of amino acids and dextrose are physiologic. Excretion into breast milk of infused amino acids and glucose mirrors normal plasma constituents. No adverse effects on nursing infant expected. M/P ratio not applicable as components are endogenous substances. Use during breastfeeding with caution only if clearly needed and with monitoring of maternal metabolic status. |
| Teratogenic Risk | No well-controlled studies in pregnant women. Parenteral nutrition is essential for maternal and fetal health when oral/enteral intake is inadequate. Amino acids and dextrose are normal constituents of fetal circulation. Risk of fetal harm is low when used as indicated. However, potential risks include maternal metabolic complications (e.g., hyperglycemia, electrolyte imbalances) that may indirectly affect the fetus. No specific teratogenic effects reported. |
■ FDA Black Box Warning
Not for use in patients with known hypersensitivity to any component. Contains aluminum that may be toxic with prolonged administration.
| Serious Effects |
["Hypersensitivity to any ingredient (e.g., amino acids, dextrose)","Uncontrolled hyperglycemia","Severe metabolic acidosis","Anuria or oliguric renal failure","Inborn errors of amino acid metabolism (e.g., phenylketonuria)"]
| Precautions | ["Risk of infection due to catheter-related bloodstream infections","Fluid and electrolyte imbalances","Hyperglycemia and hypoglycemia","Aluminum toxicity with long-term use","Hepatic and renal impairment monitoring"] |
| Food/Dietary | No oral food interactions as this is administered intravenously. Monitor oral intake if transitioning to enteral nutrition. Avoid concomitant use of oral medications that require food for absorption. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, electrolytes, renal function, liver function, acid-base balance, and serum triglycerides. Assess for signs of infection at catheter site. Fetal monitoring includes ultrasound for growth and well-being, non-stress test or biophysical profile as clinically indicated. Monitor for maternal fluid overload, hyperglycemia, and electrolyte disturbances that could affect fetal status. |
| Fertility Effects | No known direct effects on fertility. Malnutrition states requiring parenteral nutrition may impair fertility; correction of nutritional status may improve reproductive function. However, no specific studies on this product's effect on fertility. |
| Clinical Pearls | Administer via central line due to high osmolality (~2100 mOsm/L). Monitor for hyperglycemia, fluid overload, and electrolyte imbalances. Do not use as a protein source alone; ensure adequate non-protein calories are provided. Check serum triglycerides if lipids are co-administered. |
| Patient Advice | This solution provides nutrition through your vein and is not for oral use. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Tell your healthcare provider if you experience headache, confusion, or excessive thirst. · You may need frequent blood tests to monitor your blood sugar, electrolytes, and kidney function. · Do not stop the infusion abruptly without medical advice. |